852291-44-2

Upstream product

• 55362-80-6 9-bromononan-1-ol 
• 171722-92-2 4-piperidyl N-(2-biphenyl)carbamate 

Downstream Products

• 743460-70-0 C₄₅H₆₇N₃O₅Si 
• 743460-20-0 THRX-198321 
• 743460-27-7 biphenyl-2-yl-carbamic acid 1-{9-[(R)-2-(tert-butyldimethylsilanyloxy)-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]nonyl}piperidin-4-yl ester 
• 1289178-45-5 C₄₁H₅₁N₃O₂ 
• 743460-16-4 biphenyl-2-ylcarbamic acid 1-{9-[2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]nonyl}piperidin-4-yl ester 
• 743460-72-2 biphenyl-2-ylcarbamic acid 1-{9-[(R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethylamino]nonyl}piperidin-4-yl ester 
• 743460-71-1 C₃₉H₅₃N₃O₅ 

Relevant academic research and scientific papers

Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules

We sought to design dual pharmacology bronchodilators targeting both the M3 muscarinic acetylcholine and beta-2 adrenergic (β2) receptors by applying our multivalent approach to drug discovery. Herein, we describe our initial discovery and the SAR of the first such compounds with matched potencies at both receptors.

Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

The invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7a, R7b, W, G1, G2, a, b, c, d and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.